Download
s00277-020-04274-1.pdf 263,36KB
WeightNameValue
1000 Titel
  • Use of carbapenems and glycopeptides increases risk for Clostridioides difficile infections in acute myeloid leukemia patients undergoing intensive induction chemotherapy
1000 Autor/in
  1. Ballo, Olivier |
  2. Kreisel, Eva-Maria |
  3. Eladly, Fagr |
  4. Brunnberg, Uta |
  5. Stratmann, Jan |
  6. Hunyady, Peter |
  7. Hogardt, Michael |
  8. Wichelhaus, Thomas A. |
  9. Kempf, Volkhard A. J. |
  10. Steffen, Björn |
  11. Vehreschild, Joerg J. |
  12. Vehreschild, Maria J. G. T. |
  13. Finkelmeier, Fabian |
  14. Serve, Hubert |
  15. Brandts, Christian H. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-24
1000 Erschienen in
1000 Quellenangabe
  • 99(11):2547-2553
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00277-020-04274-1 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536157/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Patients with acute myeloid leukemia (AML) are often exposed to broad-spectrum antibiotics and thus at high risk of Clostridioides difficile infections (CDI). As bacterial infections are a common cause for treatment-related mortality in these patients, we conducted a retrospective study to analyze the incidence of CDI and to evaluate risk factors for CDI in a large uniformly treated AML cohort. A total of 415 AML patients undergoing intensive induction chemotherapy between 2007 and 2019 were included in this retrospective analysis. Patients presenting with diarrhea and positive stool testing for toxin-producing Clostridioides difficile were defined to have CDI. CDI was diagnosed in 37 (8.9%) of 415 AML patients with decreasing CDI rates between 2013 and 2019 versus 2007 to 2012. Days with fever, exposition to carbapenems, and glycopeptides were significantly associated with CDI in AML patients. Clinical endpoints such as length of hospital stay, admission to ICU, response rates, and survival were not adversely affected. We identified febrile episodes and exposition to carbapenems and glycopeptides as risk factors for CDI in AML patients undergoing induction chemotherapy, thereby highlighting the importance of interdisciplinary antibiotic stewardship programs guiding treatment strategies in AML patients with infectious complications to carefully balance risks and benefits of anti-infective agents.
1000 Sacherschließung
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Leukemia, Myeloid, Acute/microbiology [MeSH]
lokal Risk Factors [MeSH]
lokal Original Article
lokal Male [MeSH]
lokal Length of Stay [MeSH]
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Enterocolitis, Pseudomembranous/drug therapy [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Incidence [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Clostridium difficile [MeSH]
lokal CDI
lokal Induction chemotherapy
lokal Glycopeptides/administration
lokal Enterocolitis, Pseudomembranous/epidemiology [MeSH]
lokal Leukemia, Myeloid, Acute/epidemiology [MeSH]
lokal Induction Chemotherapy [MeSH]
lokal Leukemia, Myeloid, Acute/drug therapy [MeSH]
lokal Carbapenems/administration
lokal AML
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1634-1988|https://frl.publisso.de/adhoc/uri/S3JlaXNlbCwgRXZhLU1hcmlh|https://frl.publisso.de/adhoc/uri/RWxhZGx5LCBGYWdy|https://frl.publisso.de/adhoc/uri/QnJ1bm5iZXJnLCBVdGE=|https://frl.publisso.de/adhoc/uri/U3RyYXRtYW5uLCBKYW4=|https://frl.publisso.de/adhoc/uri/SHVueWFkeSwgUGV0ZXI=|https://frl.publisso.de/adhoc/uri/SG9nYXJkdCwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/V2ljaGVsaGF1cywgVGhvbWFzIEEu|https://frl.publisso.de/adhoc/uri/S2VtcGYsIFZvbGtoYXJkIEEuIEou|https://frl.publisso.de/adhoc/uri/U3RlZmZlbiwgQmrDtnJu|https://frl.publisso.de/adhoc/uri/VmVocmVzY2hpbGQsIEpvZXJnIEou|https://frl.publisso.de/adhoc/uri/VmVocmVzY2hpbGQsIE1hcmlhIEouIEcuIFQu|https://frl.publisso.de/adhoc/uri/Rmlua2VsbWVpZXIsIEZhYmlhbg==|https://frl.publisso.de/adhoc/uri/U2VydmUsIEh1YmVydA==|https://frl.publisso.de/adhoc/uri/QnJhbmR0cywgQ2hyaXN0aWFuIEgu
1000 Hinweis
  • DeepGreen-ID: 80f6d78a820a4b04b76fea46ff59d3bb ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6467014.rdf
1000 Erstellt am 2023-11-17T05:32:32.915+0100
1000 Erstellt von 322
1000 beschreibt frl:6467014
1000 Zuletzt bearbeitet 2023-12-01T05:19:44.541+0100
1000 Objekt bearb. Fri Dec 01 05:19:44 CET 2023
1000 Vgl. frl:6467014
1000 Oai Id
  1. oai:frl.publisso.de:frl:6467014 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source